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Effectiveness of continuous versus pulsed short-wave 
diathermy in the management of knee osteoarthritis:  
A randomized pilot study 
 
 
Abstract 
Background: Short-wave diathermy (SWD) is an electrotherapeutic modality used in the 
conservative treatment of knee osteoarthritis (KOA).  Electromagnetic radiation delivered 
in continuous (cSWD) or pulse (pSWD) mode provides a deep heating effect on tissues.  
There is no consensus on outcomes of treatment with cSWD versus pSWD in KOA. The 
aim of this study was to compare the effects of cSWD versus pSWD on pain, functionality 
and walking distance in KOA. 
Methods: 34 female patients aged 49-65 with KOA were randomized into two groups.  A 
total of 27 patients completed the study. One group (n=11) was treated with cSWD, the 
other (n=16) with pSWD for three weeks. Patients were assessed before, after and at one 
month post therapy. Outcome measures included visual analogue scale (VAS) for knee 
pain, Western Ontario and Mcmaster University Osteoarthritis Index (WOMAC) and a six-
minute walking test (6MWT). 
Results: Based on the minimal clinically important improvement (MCII), there was a 
reduction in VAS and WOMAC scores in both cSWD and pSWD groups post treatment  
(-37.3mm, 31.2mm respectively for VAS and 26%, 23% respectively for WOMAC) and at 
one month post treatment. There was no difference in pre and post treatment VAS for pain, 
WOMAC or 6MWT scores between the two groups.  There was a small post treatment 
effect size on between- group 6MWT scores (Cohen’s d: 0.238). 
Conclusion: Both treatment options appear to be efficacious in reducing pain and 
improving functionality in KOA.  There was no between-group difference. A larger study 
must be conducted to consolidate these findings. 
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Knee osteoarthritis (KOA) is one of the most common forms of arthritis in the 
Western world, with a prevalence of 10 to 15% in adults over 60 years of age (1, 2). Even 
though total knee arthroplasty (TKA) is the definitive treatment for advanced KOA, KOA 
can lead to chronic joint pain, muscle weakness and loss of function in the earlier stages of 
disease; often patients require conservative and medical treatment long before surgical 
intervention would be considered (3, 4). A recent study by Losina et al. underlined the fact 
that expanding TKA eligibility increases KOA related costs substantially, further 
reiterating the need for effective non operative treatment options (5). Short-wave 
diathermy (SWD) is one of the oldest forms of electrotherapeutic modalities traditionally 
used in the treatment of symptomatic KOA (6).  
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In 1891, Nikola Tesla first noted that heat resulted from 
irradiation of tissue with high-frequency alternating current 
and pointed out its possible medical uses. In the 1930s SWD, 
its physical properties and its beneficial therapeutic uses 
became a popular topic of discussion (7). SWD provides 
electromagnetic radiation (typically at a frequency of 27.12 
MHz), either in continuous (CSWD, thermic) or pulsed 
(PSWD, athermic) mode. It is generally believed that the 
increase in tissue temperature achieved using CSWD induces 
vasodilatation, an increase in cellular activity, pain threshold 
and soft tissue extensibility and a reduction in muscle spasm 
(6, 8).  
PSWD provides radiation in the form of pulse trains (9). 
PSWD is mostly preferred for its athermal effects. It is 
believed that PSWD also enhances cellular activity (10, 11), 
with its physiological effects including an increase in blood 
flow and a decrease in joint pain and stiffness, inflammation 
and edema (12). The perceived anti-inflammatory effects of 
PSWD on the synovium, and the possible link between 
thermic SWD, increased synovitis and worsening of 
cartilaginous degeneration, (8,9) has resulted in increased 
use of PSWD in the treatment of KOA over the past ten to 
fifteen years (13).  
Despite SWD being a well established part of the 
conservative treatment of knee osteoarthritis (KOA), the 
Osteoarthritis Research Society International guideline for 
the non-surgical management of KOA did not feature SWD 
(14).
 
The reason for this maybe is that even though SWD 
treatment appears to be effective in decreasing pain (15) and 
increasing muscle strength (16) in patients with KOA, there 
is no the consensus on the outcomes of treatment using 
CSWD versus PSWD.  
A systematic review and meta-analysis of the studies 
comparing the effectiveness of CSWD to PSWD published 
by Laufer et al. in 2012 concluded that findings to date 
suggested that PSWD was of no benefit (17). However, they 
did acknowledge that larger studies with comparable 
samples, protocols and outcome measures were required in 
order to draw firmer conclusions.  A more recent systematic 
review also concluded that SWD provided pain relief in 
KOA patients but that it did not improve physical function. 
However, in contrast to the previous review, robust subgroup 
analysis this time revealed that PSWD was superior to 
CSWD in reducing pain, especially in females (18). The aim 
of our study was to compare the effects of continuous 
(thermic) versus pulsed (athermic) SWD on pain, function 
and activity in women with KOA especially focusing on the 
treatment effects of SWD alone.  
 
 
Methods 
The study took place between January 2013 and January 
2016.  Thirty four age and body mass index (BMI) matched 
female patients presenting to the outpatient clinic between 
the ages of 49-65 with complaints of bilateral knee pain and 
a diagnosis of KOA according to the American College of 
Rheumatology clinical criteria for the classification of 
osteoarthritis of the knee (19) were randomized into one of 
two treatment groups (thermic SWD and athermic SWD) 
using simple random sampling. Three of the patients initially 
assigned to the thermic SWD group could not tolerate the 
heat sensation and so were reassigned to the athermic SWD 
group before treatment commencement. Only patients with 
radiographic evidence of grade 2-3 osteoarthritis according 
to the Kellgren – Lawrance (K-L) scale (20), diagnosed by 
the same Physical and Rehabilitation Medicine (PRM) 
specialist, were included in the study. Exclusion criteria: 1) 
physical therapy to the knee joint over the past six months 2) 
reduction of range of motion of the knee 3) presence of low 
back/hip/knee/ankle joint pathologies or symptoms of pain 
4) presence of inflammatory arthropathy 5) history of knee 
trauma or knee intervention over the past six months 6) 
presence of metal implants, a cardiac pacemaker or 
malignancy. Those taking non steroidal anti-inflammatory 
drugs (NSAIDs) were switched to diclofenac 75mg slow 
release once daily one week prior to treatment for the 
duration of the study. Written informed consent was 
obtained from all study participants prior to commencement 
of the study. 
Physical Therapy Modality: SWD electromagnetic 
radiation at a frequency of 27.12MHz was applied in 
continuous mode (CSWD, thermic) in group one and pulsed 
mode (PSWD, athermic) in group two. Treatment was 
administered by the same physiotherapists using the 
Curapuls 419 SWD machines (Enraf-Nonius, Delft, the 
Netherlands). No other physical therapy was given. Sessions 
lasted fifteen minutes, on five consecutive days per week for 
a total of three weeks.  
Assessment of Treatment effects: Patients were assessed 
before, after and in one month post treatment. All 
assessments were carried out by the same PRM physician 
blind to the treatment received and knee radiographs. The 
 Caspian J Intern Med 2019; 10(4):431-438  
Continous versus pulsed short wave diathermy in vnee osteocorthritis                                               433 
 
primary outcome measure was pain, measured using a visual 
analogue scale (VAS). The VAS provides a subjective, 
visual pain score from 0-100mm scored by the patient where 
0mm is no pain and 100mm the worst pain imaginable. 
Secondary outcome measures included the Western Ontario 
and Mcmaster University Osteoarthritis Index (WOMAC) 
and a-six minute walking test (6MWT) as a functional test of 
walking ability and exercise capacity (21, 22). All 6MWTs 
were performed in the same ten meter long gymnasium.  The 
WOMAC aims to evaluate clinically important, 
patient‐relevant changes in health status as a result of 
treatment intervention to the knee (21).  
Ethical approval for the project was obtained from the 
Ankara University Faculty of Medicine Ethics Committee 
(decision no 10-417-13) in accordance with ethical standards 
on human experimentation and with the Helsinki Declaration 
of 1975, as revised in 1983. No financial support was 
received for the project. 
Statistical Analysis: Articles on adequate sample sizes for 
pilot studies was used and a sample size of between ten and 
thirty patients was aimed for (23). The data was analyzed 
using SPSS for Windows (IBM
®
 SPSS
® 
statistics version 
22). Chi square and Fisher’s exact tests were used for the 
cross tabs of categorical date.  
The normal distribution and homogeneity of the 
continuous variables were evaluated using the Kolmogorov- 
Smirnov test and Levene’s test respectively. p<0.05 signified 
an abnormal distribution/ non-homogeneity in which case 
non - parametric tests were used for further analysis. The 
student’s T test was used when comparing between group of 
parametric data and Mann Whitney U test for non-parametric 
data.  
The Friedman test was used to evaluate within and 
between group VAS and WOMAC scores. ANOVA with 
repeated measurements was used to compare within group 
6MWT and for all the patients regardless of treatment group. 
When a statistically significant result was obtained, the post 
hoc Bonferroni multiple comparison test was used to identify 
pair wise differences.  
Minimal clinically important differences (MCID) 
/improvement (MCII) for VAS, WOMAC and 6MWT were 
used when interpreting the data. The MCII for the VAS 
score for pain in KOA was -19.9mm (24). In rehabilitation 
intervention, effects larger than 12% of the baseline score 
can be used as the MCID in the WOMAC (25).  Based on 
the work of Redelmeier et al. 54 meters is often used as the 
MCID for the 6MWT (26). Effect size was calculated using 
Cohen’s d where the values of d for small, medium, and 
large effects are 0.2, 0.5, and 0.8 respectively (27).  
 
 
Results 
Eleven (40.7%) patients were treated with CSWD (group 
1), sixteen (59.3%) were treated with PSWD (group 2). A 
total of seven patients randomized to the treatment groups 
were excluded from the study. Three of the seven patients 
failed to complete the treatment protocol, four of the seven 
patients were unable to attend follow up assessment one 
month after treatment (figure 1).  
Baseline characteristics of both groups have been given 
in table one. There was no statistical difference between the 
groups in terms of age distribution and BMI (P>0.05). There 
was also no statistically significant difference in the 
distribution of patients in the CSWD versus the PSWD 
group who were using NSAIDs (P=0.411). In addition, there 
was no significant difference in the Kellgren Lawrence 
grading of either the right or left knee between those taking 
NSAIDs and those on no analgesics (P=0.710 and P=0.687 
respectively).  
On assessment, there was no statistically significant 
difference in the distribution of patients with Kellgren 
Lawrence grade 2 and Kellgren Lawrence grade 3 of the 
right knee between the treatment groups (P=0.061), this was 
also the case for the left knee (P=0.224). Table 1 here. 
Based on the MCII, there was an important reduction in 
VAS scores for pain following treatment with both CWSD 
and PSWD immediately after the course of treatment (-37.3 
mm and -31.2 mm respectively) and in one-month follow up 
(table 2).  
In addition, there was a clinically important reduction in 
total WOMAC scores after treatment in both groups; the 
change in the mean WOMAC total score was 26% in the 
CSWD group and 23% in the PSWD group. The clinically 
important change in WOMAC persisted one-month follow 
up post treatment (table 3).  
No clinically important change in 6MWT was detected in 
either treatment group (table 4). There was no difference in 
pre and posttreatment VAS for pain, WOMAC or 6MWT 
scores between the two groups. When comparing the post 
treatment scores of the two groups to one another, there was 
a small effect size in the 6MWT with a Cohen’s d of 0.238. 
None of the patients reported any side effects of treatment. 
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Fig . 1 Patient enrollment flow chart 
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Table 1: Baseline patient characteristics 
Characteristics Continuous SWD† 
N=11 
 
Pulsed SWD† 
N=16 
N (%) 
Total 
N=27 
N (%) 
P (between groups) 
Age (years)Mean±SD 
Median; min- max 
 
57.9±5.0 
56; 52-65 
 
54.8±4.4 
56; 49-60 
 
56.85±5.855 
57; 49-65 
 
0.900 
BMI
α
 (kg/m
2
) Mean±SD 
Median; min- max 
 
33.6±4.1 
33.7; 26-40.6 
 
34.7 ± 4.8 
33.4; 28.9-42 
 
34.2±4.5 
33.7; 26-42 
 
0.534 
Symptom duration (months) 
Mean±SD 
Median; min- max 
 
87.6±57.5 
120.0; 4-180 
 
36.6 ± 33.3 
30;1-120 
 
57.4 ± 50.6 
48; 1-180 
 
0.039 
NSAIDs use, N (%) 5(45.5) 4(25) 9(33.3) 0.411 
Right knee KL
 
grade 2, N (%) 
Right knee KL grade 3, N (%) 
4(36.4) 
7(63.6) 
12(75) 
4(25) 
16(59.3) 
11(40.7) 
 
0.061 
Left knee KL grade 2, N (%) 
Left knee KL grade 3, N (%) 
5(45.5) 
6(54.5) 
12(75) 
4(25) 
17(63) 
10(37) 
 
0.224 
Pre treatment VAS* for pain (mm) 
Mean±SD 
Median; min- max 
 
77.3±20.0 
80; 50-100 
 
75.0±21.6 
80; 40-100 
 
75.9±20.6 
80; 40-100 
 
0.839 
Pre treatment 6MWT
◦
 (m) 
Mean±SD 
Median; min- max 
 
352.3±67.4 
350; 250-440 
 
323.3±88.3 
327.5; 80-460 
 
335.07±80.343 
340; 80-460 
 
0.367 
Pre treatment WOMAC¨ total score 
Mean±SD 
Median; min- max 
 
52.1±18.1 
54; 26-78 
 
47.9±15.3 
45; 16.73 
 
49.6±16.3 
48; 16-78 
 
0.521 
†Short-wave diathermy, αBody mass index, ∞Kellgren Lawrance *Visual analogue scale for pain (range 0-100mm), ◦6 minute walking test, ¨ Western Ontario and 
Mcmaster University Osteoarthritis Index 
 
 
Table 2: VAS scores before and after treatment in both groups 
 Continuous  
SWD 
(n= 11) 
Pulsed SWD 
(n= 16) 
Total 
(n= 27) 
P (between 
groups) 
Between group 
Cohen’s d 
Pretreatment VAS for pain (mm) 
Mean±SD 
Median; min- max 
 
77.3±20.0 
80; 50-100 
 
75.0±21.6 
80; 40-100 
 
75.9±20.6 
80; 40-100 
 
0.839 
 
Post treatment VAS for pain (mm) 
Mean±SD 
Median; min- max 
 
40.00±27.9 
40; 0-100 
 
43.8±26.2 
50; 0-90 
 
42.2±26.5 
50; 0-100 
 
0.600 
 
0.141 
1 month post treatment VAS for pain (mm) 
Mean±SD 
Median; min- max 
 
49.1±28.9 
50; 10-100 
 
49.1±28.9 
50; 0-100 
 
49.1±28.3 
50; 0-100 
 
0.980 
 
0 
P within groups 0.058 0.003 0.000   
See table 1 for abbreviations 
VAS score for pain (range 0-100mm, MCII -19.9mm)          Cohen’s d 0.2= small effect size         Cohen’s d 0.5= medium effect size 
Cohen’s d 0.8= large effect size 
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Table 3: WOMAC scores before and after treatment in both groups 
 Continuous 
SWD 
(n= 11) 
Pulsed SWD 
(n= 16) 
Total 
(n= 27) 
P (between groups) Between group 
Cohen’s d 
Pretreatment WOMAC score 
Mean±SD 
Median; min- max 
 
52.1 ± 18.1 
54; 26-78 
 
47.9 ± 15.3 
45; 16-73 
 
49.6 ± 16.3 
48; 16-78 
 
P= 0.521 
 
Post treatment WOMAC score 
Mean±SD 
Median; min- max 
 
38.4 ± 17.4 
34.0; 6-65 
 
36.9 ± 18.4 
35.5; 2-71 
 
37.5 ± 17.7 
34.0; 2-71 
 
P=0.805 
 
0.084 
1 month post treatment WOMAC score 
Mean±SD 
Median; min- max 
 
37.4 ± 20.3 
39.0; 2-62 
 
37.4 ± 23.1 
38; 0-76 
 
37.4 ± 21.6 
38; 0-76 
 
P=0.921 
 
0 
P within groups p=0.060 P= 0.003 P=0.000   
See table 1 for abbreviations 
WOMAC MCID >12% of baseline score          Cohens d 0.2= small effect size             Cohen’s d 0.5= medium effect size          Cohen’s d 0.8= large effect size  
 
Table 4: 6MWT values before and after treatment in both groups 
 Continuous 
SWD 
(n= 11) 
Pulsed SWD 
(n=16) 
Total 
(n=27) 
P (between 
groups) 
Between group  
Cohen’s d 
Pretreatment 6MWT (m) 
Mean±SD 
Median; min- max 
 
352.3±67.4 
350; 250-440 
 
323.3±88.3 
327.5; 80-460 
 
335.1 ± 80.3 
340; 80-460 
 
t=-0.920 
p=0.367 
 
Post treatment 6MWT (m) 
Mean±SD 
Median; min- max 
 
361.0±70.9 
358; 260-500 
 
344.4±68.8 
360; 200-440 
 
351.2±68.8 
358.0; 200-500 
 
t= -0.610 
p=0.548 
 
0.238 
1 month post treatment 6MWT (m) 
Mean±SD 
Median; min- max 
 
365.9±73.9 
392; 260-483 
 
363.6±87.8 
348; 200-504 
 
364.52±80.9 
355; 200-504 
 
t=-0.073 
p=0.943 
 
0.028 
P within groups P= 0.300 P= 0.010 P=0.041   
See table 1 for abbreviations 
6MWT MCID 54m                Cohens d 0.2= small effect size            Cohen’s d 0.5= medium effect size                 Cohen’s d 0.8= large effect size  
 
Discussion 
The findings of this comparative effectiveness study 
suggest that both continuous and pulsed SWD reduce pain 
and improve functionality, but not walking capacity in KOA. 
The small effect size is in keeping with the fact that one 
treatment option was not found to be superior to the other. 
To date, published research in the literature also highlights 
the benefits of both CSWD and PSWD.   
The most recent systematic review and meta analysis on 
the treatment effects of SWD in KOA by Wang et al. has 
emphasized the increased reduction in pain following 
treatment with PSWD as opposed to CSWD (18). It is  
 
 
believed that the ability of PSWD to reduce inflammation 
and synovial thickness results in a reduction in joint stiffness 
and pain (28). This may explain its significant effects on 
pain and functionality in this study.  
In contrast, some past studies have shown that the 
positive effect on pain perception is achieved only when the 
treatment involves at least some degree of thermal sensation 
but that despite this, the benefits of pain reduction are lost 
within 9-12 weeks of follow up post therapy. Contrary to 
this, the study by Akyol et. al showed no extra positive 
effects of thermic SWD plus isokinetic exercise on pain, 
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disability, muscle strength, walking distance in KOA when 
compared to exercise alone (29). 
There was no clinically important improvement in 
walking distance as measured by the 6MWT. Laufer at al. 
also found no significant improvement in a three-minute 
walking test following treatment with thermic and athermic 
SWD (30). A meta-analysis conducted by the same author 
suggested a strong possibility of an immediate improvement 
on pain and functional abilities, as reported by the WOMAC 
questionnaire, following treatment with SWD (17). 
The main limitation to the study was the small sample 
size. This was partly due the stringent exclusion criteria; 
many women with gonarthrosis in the 50-65 age range also 
suffer from low back and hip complaints. However, it was 
believed that the presence of such symptoms could confound 
the results and so these patients were excluded from the 
study. Even though the beneficial effects of SWD in the 
treatment of KOA are well known, many patients declined 
treatment with SWD. Therefore, patient recruitment may 
become a problem when considering the feasibility of this 
study on a larger scale. Even though the benefits of regular 
long term exercise are known, monitoring exercise 
compliance, especially in the long term maybe difficult. In 
addition, a sham SWD group can be added to future studies.  
In conclusion, the preliminary results of this pilot study 
suggest that treatment of KOA with both CSWD and PSWD 
is effective at reducing pain and improving functionality.  
However, a further study with a larger sample size must be 
performed to consolidate these findings.  
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